{"url":"https://lda.senate.gov/api/v1/filings/1d673159-b70b-46b2-bc5e-ebbce83cc2e7/","filing_uuid":"1d673159-b70b-46b2-bc5e-ebbce83cc2e7","filing_type":"1T","filing_type_display":"1st Quarter - Termination","filing_year":2017,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/1d673159-b70b-46b2-bc5e-ebbce83cc2e7/print/","filing_document_content_type":"text/html","income":null,"expenses":"210000.00","expenses_method":"a","expenses_method_display":"Method A - Reporting amounts using LDA definitions only","posted_by_name":"Sara Froelich","dt_posted":"2017-07-20T10:05:34.253000-04:00","termination_date":"2017-03-31","registrant_country":"United States of America","registrant_ppb_country":"United States of America","registrant_address_1":"1455 Pennsylvania Ave., NW","registrant_address_2":"Suite 500","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":16054,"url":"https://lda.senate.gov/api/v1/registrants/16054/","house_registrant_id":30257,"name":"GENZYME CORPORATION","description":null,"address_1":"1455 Pennsylvania Ave., NW","address_2":"Suite 500","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"SARA FROELICH","contact_telephone":"+1 202-585-3031","dt_updated":"2022-04-06T16:04:30.357016-04:00"},"client":{"id":121531,"url":"https://lda.senate.gov/api/v1/clients/121531/","client_id":12,"name":"GENZYME CORPORATION","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-08-10"},"lobbying_activities":[{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"Patent settlement legislation\nPreserve Access to Affordable Generics Act\nCreating and Restoring Equal Access to Equivalent Samples Act","foreign_entity_issues":"As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.","lobbyists":[{"lobbyist":{"id":41087,"prefix":null,"prefix_display":null,"first_name":"SARA","nickname":null,"middle_name":null,"last_name":"FROELICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61078,"prefix":null,"prefix_display":null,"first_name":"MELISSA","nickname":null,"middle_name":null,"last_name":"BARTLETT","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Trade legislation and other trade authority\nProtection and promotion of 12 years exclusivity for biologics\nProtection and promotion of Orphan Drug Act market exclusivity","foreign_entity_issues":"As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.","lobbyists":[{"lobbyist":{"id":41087,"prefix":null,"prefix_display":null,"first_name":"SARA","nickname":null,"middle_name":null,"last_name":"FROELICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61078,"prefix":null,"prefix_display":null,"first_name":"MELISSA","nickname":null,"middle_name":null,"last_name":"BARTLETT","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of health Care and Education Reconciliation Act (P.L. 111-152)\nExcise tax for drugs and biologics\nIssues and policies related to Orphan Drug Tax Credit\nImplementation of American Taxpayer Relief Act of 2012\nIssues and policies related to tax reform, including border adjustable tax\nCorporate tax inversion\nLegislation pertaining to the applicability of the ACA tax carve out for non-orphan designated drugs","foreign_entity_issues":"As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.","lobbyists":[{"lobbyist":{"id":41087,"prefix":null,"prefix_display":null,"first_name":"SARA","nickname":null,"middle_name":null,"last_name":"FROELICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61078,"prefix":null,"prefix_display":null,"first_name":"MELISSA","nickname":null,"middle_name":null,"last_name":"BARTLETT","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Implementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconcilation Act (P.L. 111-152)\n340B issues and legislative reform proposals \nIssues related to importation of prescription drugs\nHealth technology assessment of orphan and specialty drugs \nImplementation of the FDA Safety and Innovation Act (FDASIA) (P.L. 112-144)\nH.R. 1628, American Health Care Act of 2017\nH.R. 1231, RACE for Children Act \nS. 456, RACE for Children Act\nPreserve Access to Affordable Generics Act\nH.R. 878, Right To Try Act of 2017\nS. 204, Trickett Wendler Right To Try Act of 2017\nCreating and restoring Equal Access to Equivalent Samples Act\nH.R. 314, Health Care Choice Act of 2017\nS. 191, Patient Freedom Act of 2017\nH.R. 184, Protect Medical Innovation Act of 2017\nRegulation of innovative biologic products for neurodegenerative diseases\nIssues and policies related to implementation of Orphan Drug Act and orphan drug development\nImplementation of newborn screening programs\nIssues and policies related to biosimilars exclusivity period, including FDA guidance\nIssues and polices related to FDA oversight and management, including workforce authorities modernization\nIssues and policies related to expanded access programs\nLegislation pertaining to FDA priority review vouchers,generally\nIssues related to the value of prescription medicines, including affordability\nDrug shortage issues\nIssues related to health care transparency","foreign_entity_issues":"As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.","lobbyists":[{"lobbyist":{"id":41087,"prefix":null,"prefix_display":null,"first_name":"SARA","nickname":null,"middle_name":null,"last_name":"FROELICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61078,"prefix":null,"prefix_display":null,"first_name":"MELISSA","nickname":null,"middle_name":null,"last_name":"BARTLETT","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Medicare Part D coverage and patient access policies\nESRD bundling and drug reimbursement issues\nHCPCS coding and reimbursement decisions\nImplementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152)\nLeast Costly Alternative (LCA) policy\nChanges regarding Medicare Part B and Average Sales Price\nMedicare secondary payor for ESRD services\nExtension of rebates on Medicare Part D drugs\nPerformance measures for bone and mineral metabolism for ESRD program\nImplementation of American Taxpayer Relief Act of 2012\nAccess of ESRD patients to Medicare Advantage plans\nChronic kidney care improvement","foreign_entity_issues":"As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.","lobbyists":[{"lobbyist":{"id":41087,"prefix":null,"prefix_display":null,"first_name":"SARA","nickname":null,"middle_name":null,"last_name":"FROELICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61078,"prefix":null,"prefix_display":null,"first_name":"MELISSA","nickname":null,"middle_name":null,"last_name":"BARTLETT","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Funding for FDA and NIH\nIssues and policies related to FY 2017 and FY 2018 appropriations and all applicable amendments\nIssues associated with budget reconciliation processes","foreign_entity_issues":"As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.","lobbyists":[{"lobbyist":{"id":41087,"prefix":null,"prefix_display":null,"first_name":"SARA","nickname":null,"middle_name":null,"last_name":"FROELICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61078,"prefix":null,"prefix_display":null,"first_name":"MELISSA","nickname":null,"middle_name":null,"last_name":"BARTLETT","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Implementation of Food and Drug Safety and Innovation Act (FDASIA)\nIssues and policies related to biosimilars exclusivity period\nBiosimilars FDA guidance\nImplementation of Patient Protection & Affordable Health Care Act (P.L. 111-148) and Implementation of Health Care and Education Reconciliation Act (P.L. 111-152)\nIssues and policies related to FDA oversight and management \nIssues and policies related to expanded access programs\nIssues and policies related to patient involvement with FDA decision making\nS. 204, Trickett Wendler Right to Try Act of 2017\nH.R. 878, Right to Try Act of 2017","foreign_entity_issues":"As the ultimate parent of Genzyme Corporation, Sanofi SA, identified on Form LD-1, has an interest in the issues lobbied.","lobbyists":[{"lobbyist":{"id":41087,"prefix":null,"prefix_display":null,"first_name":"SARA","nickname":null,"middle_name":null,"last_name":"FROELICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61078,"prefix":null,"prefix_display":null,"first_name":"MELISSA","nickname":null,"middle_name":null,"last_name":"BARTLETT","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}